Drug
Denosumab
Denosumab: highest development phase Post-Market, developed by Amgen. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Denosumab NCT03301857 | Post-Market | Giant Cell Tumor of Bone |
| denosumab NCT02101164 | Post-Market | Solid Tumor |
| Denosumab NCT01464931 | Phase 1 | Renal Impairment |
Latest
No recent events.
Follow Denosumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.